CD274 and cancer: In cancer immunotherapy, targeting this axis with PD-1 or PD-L1 inhibitors enables a more robust immune attack by not only enhancing T cell activity but also by potentially increasing the phagocytic capabilities of macrophages and dendritic cells, allowing for more effective recognition and elimination of tumor cells (54, 74).